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Abstract: Chitosan has been the subject of interest for its use as a polymeric drug carrier 
material in dosage form design due to its appealing properties such as biocompatibility, 
biodegradability, low toxicity and relatively low production cost from abundant natural 
sources. However, one drawback of using this natural polysaccharide in modified release 
dosage  forms  for  oral  administration  is  its  fast  dissolution  rate  in  the  stomach.  Since 
chitosan is positively charged at low pH values (below its pKa value), it spontaneously 
associates with negatively charged polyions in solution to form polyelectrolyte complexes. 
These  chitosan  based  polyelectrolyte  complexes  exhibit  favourable  physicochemical 
properties with preservation of chitosan‟s biocompatible characteristics. These complexes 
are therefore good candidate excipient materials for the design of different types of dosage 
forms.  It  is  the  aim  of  this  review  to  describe  complexation  of  chitosan  with  selected 
natural and synthetic polyanions and to  indicate some of the factors that influence the 
formation  and  stability  of  these  polyelectrolyte  complexes.  Furthermore,  recent 
investigations into the use of these complexes as excipients in drug delivery systems such as 
nano- and microparticles, beads, fibers, sponges and matrix type tablets are briefly described. 
Keywords:  chitosan;  polyelectrolyte  complex;  self  assembly;  drug  delivery;  
modified release 
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1. Introduction 
Mixing  oppositely  charged  polyelectrolytes  in  solution  will  result  in  their  self  assembly  or 
spontaneous association due to the formation of strong, but reversible electrostatic links. These direct 
interactions between the polymeric chains lead to the formation of polyelectrolyte complex networks 
with  non-permanent  structures  while  avoiding  the  use  of  covalent  cross-linkers.  In  general,  these 
polymeric networks or hydrogels are well tolerated, biocompatible and are more sensitive to changes 
in  environmental  conditions  [1,2].  The  formation  and  stability  of  these  polyelectrolyte  complexes 
depend  on  many  factors  such  as  the  degree  of  ionization  of  each  of  the  oppositely  charged 
polyelectrolytes, the density of the charges on the polyelectrolytes, the charge distribution over the 
polymeric chains, the concentration of the polyelectrolytes, their mixing ratio, the mixing order, the 
duration of the interaction, the nature of the ionic groups, the position of the ionic groups on the 
polymeric chains, the molecular weight of the polyelectrolytes, the polymer chain flexibility as well as 
the temperature, ionic strength and pH of the reaction medium [3–6]. When polyelectrolytes are mixed 
in such a ratio that there is an excess of one charge (either positive or negative), a non-stoichiometric 
complex  is  formed  that  are  usually  soluble.  On  the  other  hand,  a  stoichiometric  polyelectrolyte 
complex  contains  equal  amounts  of  each  opposite  charge  with  a  zero  net  charge  in  the  resultant 
complex.  Stoichiometric  polyelectrolyte  complexes  are  usually  insoluble  and  precipitate  out  of 
solution upon formation [7]. 
Chitosan  refers  to  a  series  of  polymers  that  are  deacetylated  derivatives  of  the  natural 
polysaccharide, chitin, with different degrees of deacetylation and molecular weights. It is composed 
of  -1,4-linked  glucosamine  (deacetylated  units)  and  N-acetyl-D-glusoamine  (acetylated  units)  
(Figure 1) with typical degrees of deacetylation between 70 and 95% and molecular weights between 
10  and  1,000  kDa  [8,9].  Highly  refined  grades  of  chitosan  have  been  used  in  pharmaceutical 
formulations  as  a  release-controlling  agent  in  oral  preparations  [10].  Although  chitosan  is  a  very 
promising biopolymer for use as carrier material in drug delivery systems, it has a limited capacity for 
controlling drug release from oral dosage forms due to its fast dissolution in the stomach. To overcome 
this  disadvantage,  chemical  modifications  such  as  co-polymerisation  or  derivatisation  have  been 
applied.  However,  this  approach  leads  to  the  formation  of  new  chemical  entities  with  unknown 
toxicological profiles and a physical modification of the polymer is therefore rather preferred. Three 
dimensional  polymeric  networks  or  complexes  prepared  by  non-covalent  strategies  rely  on 
electrostatic, hydrophobic and/or hydrogen bonding forces between the polymeric chains rather than 
chemical bonds. These inter-polymer chain interactions are physical in nature and reversible but can 
provide  the  required  properties  for  optimal  drug  delivery  if  the  correct  polymers  are  
combined [5,11,12].  
The cationic amino groups on the C2 position of the repeating glucopyranose units of chitosan can 
interact electrostatically with the anionic groups (usually carboxylic acid groups) of other polyions to 
form polyelectrolyte complexes. Many different polyanions from natural origin (e.g. pectin, alginate, 
carrageenan,  xanthan  gum,  carboxymethyl  cellulose,  chondroitin  sulphate,  dextran  sulphate, 
hyaluronic acid) or synthetic origin (e.g., poly (acrylic acid)), polyphosphoric acid, poly (L-lactide) 
have  been  used  to  form  polyelectrolyte  complexes  with  chitosan  in  order  to  provide  the  required 
physicochemical properties for the design of specific drug delivery systems [2]. Mar. Drugs 2010, 8                                    
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Figure  1.  Chemical  structure  of  chitosan  consisting  of  N-acetyl-D-glucosamine  and 
glucosamine units. 
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Chitosan complexes have been used in a wide range of pharmaceutical applications such as those 
formed with DNA to serve as non-viral vectors for gene delivery [13] and complexes formed between 
chitosan  and  anionic  polymers  have  been  investigated  for  use  as  biosensors,  scaffolds  in  tissue 
engineering, for waste-water treatment  and  for drug  delivery  in  different forms  [14].  Most  of the 
investigated polycomplexes that involve chitosan are those formed with other polysaccharides, which 
are  divided  into  natural  polysaccharides  (including  phytopolysaccharides,  zoopolysaccharides  and 
microorganism polysaccharides) and synthetic polysaccharides [15]. This review specifically focuses 
on polyelectrolyte complexes formed between chitosan and selected natural and synthetic polyanions 
that have been investigated as excipients in modified release drug delivery systems such as matrix type 
tablets, beads, sponges, microparticles or nanoparticles for different routes of administration. 
2. Polyelectrolyte Complexes between Chitosan and Natural Polymers 
Many different polyelectrolyte complexes between chitosan and anionic natural polymers have been 
prepared and investigated. However, some of these polyelectrolyte complexes have been formed and 
characterised  but  not  yet  investigated  for  drug  delivery  purposes  such  as  those  formed  between 
chitosan and polygalacturonic acid [16], sodium dextransulfate [17], carboxymethyl cashew gum [18], 
fibroin  [19],  sodium  carboxymethyl  cellulose  [20]  and  “angico”  gum  [21].  Therefore,  only  the 
following selected natural polyanions will be described in more detail in terms of their polyelectrolyte 
complexes with chitosan namely alginate, carrageenan, pectin, xanthan gum, hyaluronic acid, gum 
kondagogu,  gelatine,  poly--glutamic  acid  and  maleic  starch  half-ester.  Furthermore,  only 
polyelectrolyte complexes prepared without the addition of chemical cross-linkers are considered here. 
2.1. Chitosan-alginate polyelectrolyte complex 
Alginate is  a  natural,  linear, unbranched, biodegradable polysaccharide  consisting of 1,4-linked  
-D-mannuronic acid and -L-guluronic acid monomers in varying proportions (Figure 2). Alginates 
are extracted from brown seaweeds and marine algae such as Laminaria hyperborea, Ascophyllum 
nodosum  and  Macrocystis  pyrifera  [22,23].  The  negatively  charged  carboxylic  acid  groups  of 
manuronic and guluronic acid units in alginate interact electrostatically with the positively charged 
amino groups of chitosan to form a polyelectrolyte complex. Alginate is one of the most studied 
anionic polyelectrolytes in complexation with chitosan because the polyelectrolyte complex formed Mar. Drugs 2010, 8                                    
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between these two polymers is still biodegradable and biocompatible but mechanically stronger at 
lower pH values where chitosan dissolves [24]. 
Figure 2. Chemical structure of alginate. 
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A study on the biodegradation of chitosan-alginate polyelectrolyte complexes showed that while 
chitosan (with a low degree of deacetylation) alone was effectively degraded by lysozymes, the effect 
of these enzymes on the polyelectrolyte complex was negligible. The polyelectrolyte complex did 
show a high ability of lysozyme adsorbtion, but enzymatic degradation was hindered by the strong 
interaction  between  the  chitosan  and  alginate  polymeric  chains.  However,  the  polyelectrolyte 
complexes showed partial degradation by means of hydrolysis. Since the rate of biodegradation may be 
regulated by changing the polymer ratio, it indicates that this particular polyelectrolyte complex has a 
high potential in tissue engineering for scaffolds and support materials [25].  
It was shown that charge ratio, molecular weight, ionic strength, pH, mixing order as well as speed 
and  diameter  of  the  dispersing  element  influence  the  particle  size,  particle  surface  charge  
(zeta potential) and stability of alginate-chitosan polyelectrolyte complexes [26]. In a study wherein 
chitosan and alginate were reacted in their completely ionised states by maintaining the pH values of 
each polymer‟s solution at a specific value (i.e., pH 2 for the chitosan solution and pH 6.5 for the 
alginate solution) polyelectrolyte complex beads were formed that showed improved stability of the 
entrapped -amylase. The selected pH values ensured an increased charge density on each polymer 
and led to intense cross-linking during polyelectrolyte complex formation and consequently beads with 
small  micropores  were  formed.  In  addition,  the  chitolytic  activity  of  -amylases  was  almost 
completely suppressed in the acidic environment [22]. 
Chitosan-alginate  polyelectrolyte  complex  fibers  showed  promising  results  for  controlling  the 
release of charged molecules and exhibited high encapsulation efficiencies of these molecules [27].  
A comparison of matrix type tablets made of the polyelectrolyte complexes formed between chitosan 
and alginate and those formed between chitosan and carrageenan showed that the former was better in 
prolonging diltiazem release at lower concentration of the polymers [28].  
2.2. Chitosan-carrageenan polyelectrolyte complex 
Carrageenan is the generic name for a family of high molecular weight sulphated polysaccharides 
obtained from certain species of red seaweeds. There are three basic types of carrageenan, namely 
kappa (κ), iota (ι) and lambda (λ) carrageenan (Figure 3) [23,29]. 
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Figure 3. Chemical structures of (a) λ-carrageenan, (b) ι-carrageenan and (c) κ-carrageenan. 
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It was shown that the nature or type of carrageenan considerably influence the characteristics of the 
polyelectrolyte  complex  that  is  formed  with  chitosan.  The  mechanical  strength  of  polyelectrolyte 
complex gels formed between chitosan and different carrageenans were in the order  - > - > -
carrageenan and although the latter two formed stronger gels due to the formation of more cross-links 
as a result of their double helix secondary structures, these gels were also more brittle. Furthermore, 
the  gels  obtained  for  -  and  -carrageenan  were  temperature  sensitive  because  of  the  helix–coil 
conformational transitions in their molecules [30]. 
An  investigation  was  done  on  the  potential  of  polyelectrolyte  complexes  between  -,  -,  -
carrageenan  and  chitosan  to  form  controlled  release  systems  for  glucose  oxidase.  The  complex 
between chitosan and -carrageenan showed high encapsulation efficiencies for glucose oxidase while 
having the lowest release rate for this compound. Furthermore, this complex was able to protect the 
encapsulated glucose oxidase against degradation in pH 1.2 solution, in a chitosanase solution and in a 
pepsin solution [31]. 
2.3. Chitosan-pectin polyelectrolyte complex 
The polysaccharides of the plant cell wall consist mainly of cellulose, hemicelluloses and pectin. 
Pectin is a linear polysaccharide composed of α-1,4-linked D-galacturonic acid units, however, this 
linear  structure  is  interrupted  with  highly  branched  regions  in  the  polymer  chain  (Figure  4).  The 
composition of the pectin molecule varies from source to source, e.g. pectin from citrus fruit contains 
less neutral sugars and has a smaller molecular size than pectin from apples [32–34]. 
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Figure 4. Chemical structure of pectin. 
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When acidic chitosan and pectin solutions are mixed a homogenous solution is obtained without 
any ionic interactions between the two polymers. A polyelectrolyte complex could be obtained by 
adjusting  the  pH  of  this  mixture  to  a  value  of  5.5  where  electrostatic  interactions  between  the 
negatively  charged  carboxylic  acid  groups  of  pectin  and  the  positively  charged  amino  groups  of 
chitosan occurred. As expected, the extent of this interaction depended on the pH of the surrounding 
medium which determined the extent of ionization of the polymers [14]. 
Polyelectrolyte  complexes  composed  of  chitosan  and  pectin  were  compressed  into  tablets  with 
vancomycin  as  model  drug.  The  tablets  showed  a  pH  sensitive  swelling  ability with  drug  release 
behaviour  based  on  enzyme  dependent  degradation  in  the  presence  of  beta-glucosidase,  which 
indicated potential for colon-specific delivery of vancomycin [35].  
2.4. Chitosan-xanthan gum polyelectrolyte complex 
Xanthan  gum  is  an  exopolysaccharide  secreted  from  Xanthomonas  campestris.  It  consists  of  a 
cellulosic backbone, namely -(1,4)-D-glucopyranose glucan, with a trisaccharide side chain, namely 
(3,1)--D-mannopyranose-(2,1)--D-glucuronic  acid-(4,1)--D-mannopyranose,  on  every  second 
glucose residue (Figure 5) [36]. 
Figure 5. Chemical structure of xanthan gum. 
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Results  obtained  from  a  modulated  differential  scanning  calorimetry  analysis  and  the  swelling 
degree of microcapsules prepared from chitosan-xanthan gum polyelectrolyte complexes indicated that Mar. Drugs 2010, 8                                    
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the cross-linking density was interdependent on xanthan concentration, chitosan concentration and 
chitosan solution pH [37]. A kinetic analysis through rheological measurements of chitosan-xanthan 
polyelectrolyte  complex  formation  showed  that  the  coacervate  is  formed  in  two  distinctive  steps. 
Furthermore, the kinetic curve showed a classic sol-gel transition and the hydrogel is organised in a 
quasi-ordered network during coacervation. After a period of mixing the hydrogel showed a structural 
modification  and  a  stable  storage  modulus  with  solid-like  behaviour  was  obtained.  Mechanical 
grinding of the freeze-dried polyelectrolyte complex resulted in a powder with particles that have a 
suitable diameter for pharmaceutical applications [38].  
Chitosan-xanthan  polyelectrolyte  complexes  have  been  investigated  as  a  matrix  for  enzyme 
immobilisation  [39,40],  but  a  unique  application  of  this  matrix  in  the  pharmaceutical  field  is  to 
enhance the dissolution of water insoluble drugs such as fenofibrate, ursodeoxycholic acid, nifedipine 
and indomethacin [38]. 
2.5. Chitosan-hyaluronic acid polyelectrolyte complex 
Hyaluronic acid (also called hyaluronan or hyaluronate) is the only nonsulfated glycosaminoglycan 
found in the extracellular matrix throughout connective, epithelial and neural tissues. Hyaluronic acid 
is  a  linear anionic polysaccharide with  high molecular weight that consists  of    (1,3)-N-acetyl-D-
glucosamine and  (1,4)-D-glucuronic acid repeating units linked by  (13) bonds (Figure 6). It is 
produced through bacterial fermentation of streptococcus species or extracted from rooster combs, 
umbilical cords, synovial fluids or vitreous humour for commercial purposes. It has been used in 
ophthalmic surgery, arthritis treatment, in tissue engineering, a component of scaffolds for wound 
healing and implant devices [8,41,42]. 
Figure 6. Chemical structure of hyaluronic acid. 
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It  was  shown  that  the  polyelectrolyte  complex  between chitosan  and  hyaluronic  acid  protected 
hyaluronic acid against enzymatic hydrolysis, but only at pH values different from the optimal pH of 
the enzyme. The results from this study revealed that the chitosan-hyaluronic acid polyelectrolyte 
complex unfortunately had less cell proliferation and wound healing effects compared to chitosan 
alone [43].  
Chitosan-hyaluronic  acid  polyelectrolyte  complex  beads  were  prepared  and  these  beads  were 
reacted in another step with hyaluronic acid to form an outer layer around the bead, which increased 
their stability [44]. Furthermore, when hyaluronic acid was incorporated into the hydrogel prepared Mar. Drugs 2010, 8                                    
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from  chitosan  and  poly  (N-isopropylacrylamide)  it  prevented  disintegration  of  the  system  during  
in vitro drug release studies and thereby facilitated controlled release of nalbuphine [45].  
Chitosan-hyaluronic  acid  polyelectrolyte  complex  nanoparticles  loaded  with  heparin  were 
effectively internalised by rat mast cells and showed similar activity in terms of preventing histamine 
release compared to free heparin. A high degree of loading efficiency was observed (approximately 
70%) and the nanoparticles were stable in phosphate buffered saline for at least 24 h. The release of 
unfractionated  heparin  was  much  slower  (10.8%  within  12  h)  than  that  of  low  molecular  weight 
heparin (79.7% within 12 h). These results indicated the usefulness of these nanoparticles to serve as 
effective delivery systems for pulmonary administration [46]. 
2.6. Chitosan-gum kondagogu polyelectrolyte complex 
Gum kondagogu is a natural biopolymer that is obtained from the exudated gum of Cochlospermum 
gossypium, a tree growing naturally in India. It consists of a complex polysaccharide with a relatively 
high molecular weight (ranging between 9.8 × 10
5 and 2.5 × 10
7 g/mol) and therefore exhibit a high 
viscosity in solution with gelation characteristics. When the acid hydrolysed gum was characterised by 
gas  chromatography  linked  to  mass  spectrometry  (GC-MS),  the  following  monosaccharides  were 
indicated  to  be  present:  rhamnose,  galacturonic  acid,  glucuronic  acid,  -D-galactopyranose,  
-D-glucose, galactose, arabinose, mannose and fructose [47,48]. 
Chitosan-gum kondagogu polyelectrolyte complex microparticles loaded with diclofenac sodium 
showed  controlled  drug  release,  which  was  depended  on  the  pH  of  the  dissolution  medium.  A 
pharmacokinetic study of these microparticles in rats revealed that although the time to reach the peak 
plasma concentration (Tmax) was higher compared to that of free dicolfenac sodium, the extent of drug 
absorption  (area  under  the  concentration-time  curve)  was  also  increased  significantly  when 
administered in the form of the microparticles [11].  
2.7. Chitosan-gelatine polyelectrolyte complex 
Gelatine  is  a  heterogeneous  mixture  of  protein  fractions  consisting  of  single  or  multi-stranded 
polypeptides (Figure 7). It is obtained by partial hydrolysis of animal collagen derived from skin, white 
connective tissues and bones. Type A gelatine is derived from pig skin by means of acid hydrolysis 
and type B gelatine from alkaline hydrolysis of cattle hides and bones [49].  
It was shown that the polyelectrolyte complex between chitosan and gelatine can only occur at a pH 
value above 4.7 (which represents the isoelectric point of gelatin and above this value the net charge 
on  gelatine  type  B  is  negative)  and  below  6.2  (above  which  chitosan  start  to  precipitate  out  of  
solution) [50]. Chitosan-gelatine polyelectrolyte complex sponges containing tramadol hydrochloride 
were found to retard drug release, which followed Higuchi‟s diffusion mechanism over a 12 h period. 
Subcutaneous implants of these formulations in rats showed reasonable analgesic effect that could be 
maintained  for  more  than  8  h.  Furthermore,  the  polyelectrolyte  complex  between  chitosan  and  
gelatine  produced  sponges  with  improved  mechanical  properties  compared  to  sponges  containing 
chitosan alone [51].  
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Figure 7. Typical structure of gelatin. 
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2.8. Chitosan--poly(glutamic acid) polyelectrolyte complex 
Gamma  poly  (glutamic  acid)  is  a  hydrophilic  polyanion  that  is  water-soluble,  non-toxic  and 
biodegradable. This polyamino acid is formed by amide bond linkages between the amino group on the 
 carbon atom of one glutamic acid molecule and the carboxyl group on the  carbon atom of the next 
glutamic acid molecule [52].  
Figure 8. Chemical structure of -poly (glutamic acid). 
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It was shown that stable nano-sized particles can be formed as a direct result of interactions between 
the carboxylic groups of linear -poly (glutamic acid) chains and the amino groups of linear chitosan. 
The size and stability of the nanoparticles depended on factors such as medium pH, concentration and 
ratio of -poly (glutamic acid) and chitosan solutions as well as the mixing order [53].  
In  a  study  wherein  chitosan--poly  (glutamic  acid)  polyelectrolyte  complex  nanoparticles  were 
investigated  as  drug  carriers  for  targeted  drug  delivery,  it  was  shown  that  they  can  penetrate 
A2780/AD ovarian cancer cells and this penetration was significantly faster and more efficient in the 
presence of conjugated folic acid due to over expression of folate receptors on these cells [54]. It was 
shown  that  insulin  loaded  chitosan--poly  (glutamic  acid)  polyelectrolyte  complex  nanoparticles 
caused a significant hypoglycemic action in diabetic rats with a relative oral insulin bioavailability of 
15.1%  [55].  In  another  study  insulin  containing  chitosan--poly  (glutamic  acid)  polyelectrolyte 
complex nanoparticles were filled into enteric coated  capsules that resulted in approximately 20% 
relative  bioavailability  [56].  However,  it  should  be  mentioned  that  in  these  in  vivo  studies  that 
investigated  delivery  of  encapsulated  insulin,  the  nanoparticles  were  formed  by  self-assembly  of Mar. Drugs 2010, 8                                    
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chitosan and -poly (glutamic acid) in the presence of the cross-linkers such as tripolyphosphate and 
magnesium sulphate. 
2.9. Chitosan-maleic starch half-ester acid polyelectrolyte complex 
Maleic  starch  half-ester  acid  is  an  anionic  derivative  of  starch  that  produces  a  polyelectrolyte 
complex  when  combined  with  the  polycation,  chitosan.  Characterisation  and  evaluation  of  this 
complex indicated the driving force for self-assembly was electrostatic interactions. A pH sensitive 
release  of  5-fluorouracil  was  obtained  that  was  also  dependent  on  the  maleic  starch  half-ester  to 
chitosan ratio as well as the carboxyl content of maleic starch half-ester used as starting material [57].  
3. Polyelectrolyte Complexes between Chitosan and Synthetic Polymers 
3.1. Chitosan-cross-linked-poly(acrylic acid) polyelectrolyte complexes 
Polycarbophil (Noveon AA-1
®) and Carbopol are high molecular weight polymers consisting of 
acrylic acid monomers. The poly (acrylic acid) chains are cross-linked with divinyl glycol to form 
polycarbophil and polyalkenyl alcohols such as allyl ethers of pentaerythritol or allyl ethers of sucrose 
to form Carbopol. Cross-linking of the poly (acrylic acid) chains with divinyl glycol in the case of 
polycarbophil renders only 20% of the carboxylic acid groups inaccessible for interactions with other 
compounds [58]. 
The  main  mechanism  of  complexation  between  chitosan  and  Carbopol  was  found  to  be  an 
electrostatic interaction between the NH3
+ groups of chitosan and the COO
- groups of Carbopol as 
determined by FT-IR analysis. The ratio of polymers involved in polyelectrolyte complex formation 
could be controlled by the pH of the medium. Drug release from matrix type tablets prepared from 
polyelectrolyte complexes consisting of different chitosan to Carbopol ratios did not show significant 
differences at pH 1.2, but differences were clearly shown at pH 6.8 [59]. A matrix type tablet prepared 
from the polyelectrolyte complex between chitosan and Carbopol containing theophylline as model 
drug  exhibited  a  similar  drug  release  profile  as  matrix  type  tablets  prepared  from  hydroxypropyl 
methyl cellulose. The drug release was pH dependent with a diffusional release mechanism at pH 6.8 
and a relaxational release mechanism at pH 1.2 [60]. 
Films for dermal drug delivery were prepared from the polyelectrolyte complexes between chitosan 
and  polycarbophil  (Noveon  AA-1
®)  as  well  as  between  chitosan  and  Carbopol  71G  NF
®,  which 
showed promising characteristics in terms of flexibility, resistance and water vapour transmission rate. 
These  films  showed  such  great  potential  as  formulations  for  topical  and  transdermal  drug 
administration during this characterization study that it was suggested they should be investigated for 
incorporation, release and delivery of drugs [61].  
Monolithic  matrix  type  tablets  prepared  from  chitosan-polycarbophil  (Noveon  AA-1
®) 
polyelectrolyte complex as matrix former approached zero order release for two model drugs with 
different water solubilities (i.e., diltiazem and ibuprofen). The rate of the release of these two model 
drugs depended on the concentration of the polyelectrolyte complex in the formulation of the matrix 
systems. When the matrix type tablets consisted only of polyelectrolyte complex (without drug), they 
showed  a  very  high  swelling  capability  without  erosion,  which  means  the  swelling  is  completely Mar. Drugs 2010, 8                                    
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reversible upon drying without any weight loss [62]. In another study it was shown that matrix type 
tablets prepared from the polyelectrolyte complex between chitosan and polycarbophil (Noveon AA-1
®) 
were capable of slower drug release than those prepared from hydroxypropylmethylcellulose [63]. 
When insulin was included as model drug in matrix systems containing the chitosan-polycarbophil 
(Noveon AA-1
®) polyelectrolyte complex, it was shown that the mechanism of release was dependent 
on the concentration of the polyelectrolyte complex in the formulation of the matrix systems relative to 
the  other  excipients.  The  matrix  systems  which  contained  the  highest  concentration  of  the 
polyelectrolyte complex approached zero-order insulin release and exhibited erosion in conjunction 
with swelling [64]. In general, the polyelectrolyte complex between chitosan and polycarbophil has 
shown great potential as a matrix former for modified release dosage forms according to in vitro drug 
release results.  
Figure  9.  Chemical  structure  of  (a)  poly  (acrylic  acid),  (b)  polycarbophil  AA-1  and  
(c) Carbopol 974 NF. 
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3.2. Chitosan-polymethacrylate copolymer (Eudragit) polyelectrolyte complexes 
Polymethacrylate copolymers (or Eudragit) are well known film-coating agents for oral dosage 
forms  such  as  capsules  or  tablets.  Different  types  of  Eudragit  polymers  exist  which  are  synthetic 
methacrylic  acid  copolymers  consisting  of  different  ratios  of  dimethylaminoethylmethacrylates, 
methacrylic acid and methacrylic acid esters. Some of them are polycations (Eudragit E, RL, RS and NE) 
due to the presence of dimethylamino groups or quaternary amino groups, while others are polyanions 
(Eudragit L and S) due to the presence of carboxylate groups [65,66].  
The first reference to an ionic interaction between chitosan and Eudragit was in a study where 
chitosan microcores containing sodium diclofenac as model drug were microencapsulated in Eudragit 
S-100 using an oil-in-oil solvent evaporation technique for colon targeted release. The ionic interaction 
between the two polymers was confirmed by means of infrared spectroscopy and had an influence on 
the drug release profile from the microspheres [67].  
Figure 10. Chemical structure of (a) Eudragit L100 and (b) L100-55. 
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Polyelectrolyte complexes formed between chitosan with different molecular weights and Eudragit 
L100 or Eudragit L100-55 were compressed into matrix type tablets containing diclofenac sodium as 
model  drug.  Different  aspects  of  the  complex  systems  were  investigated  such  as  the  molar  ratio, 
structure, swelling and drug release profiles. Results indicated that this polyelectrolyte complex has 
high  potential  for  manufacture  of  controlled  release  drug  delivery  systems.  Factors  such  as  the 
composition of the polyelectrolyte complex in terms of polymer ratios, Eudragit type and molecular 
weight of the chitosan influenced the drug release rate from the matrix type tablets [12]. 
3.3. Chitosan-polyalkylenoxide-maleic acid polyelectrolyte complex 
By  changing  the  alkyleneoxide  chain  composition,  a  series  of  polyelkylenoxide-maleic  acid 
(PAOMA)  copolymers  can  be  synthesised  with  different  characteristics  (e.g.,  hydrophilic  or 
hydrophobic,  Figure  11).  PAOMA  is  an  anionic  polymer  that  was  used  to  form  polyelectrolyte 
complexes with chitosan in the form of films containing salicylic acid and phenol as model drugs and 
their drug release rates were evaluated. These films indicated pH dependent drug release behaviour and 
the hydrophobic PAOMA polymer also showed temperature sensitive drug release behaviour [68]. 
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Figure 11. Chemical structure of polyalkylenoxide-maleic acid copolymer.  
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The ethylene oxide (EO) ratio determines whether the copolymer is hydrophilic or hydrophobic. EO 
ratio means the molar fraction of ethylene oxide in alkylene oxide chain defined by i/(i+j) where i and j 
represent the random copolymerisation degree. 
4. Conclusions 
The scope of polymers used in dosage form design can be increased by several approaches such as 
modification of their chemical structure, by combining different polymers in physical mixtures or by 
formation  of  polymer-polymer  associations  such  as  polyelectrolyte  complexes.  Polyelectrolyte 
complexes combine unique physicochemical properties of different polymers with the advantage of 
retaining high biocompatibility. It is therefore not surprising that polyelectrolyte complexes are gaining 
importance in modern pharmaceutical technology [69]. 
From the in vitro studies conducted on chitosan-based polyelectrolyte complexes it is clear that they 
are  valuable  excipients  with  specific  properties  for  efficient  dosage  form  design,  which  may  be 
valuable in the development of modified drug delivery systems. Unfortunately, the literature lacks  
in  vivo  data  in  terms  of  drug  delivery  from  these  dosage  forms  which  makes  it  difficult  to  be 
conclusive in terms of their effectiveness as drug carriers at this stage. Since some work has been done 
on  in  vitro-in  vivo  correlations  with  chemically  cross-linked  chitosan  hydrogels  with  successful 
sustained  drug  delivery  in  animals  (e.g.,  [70]),  it  is  anticipated  that  optimized  chitosan  based 
polyelectrolyte complexes may also perform up to expectation for in vivo drug delivery. 
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